In a bid to establish greater control and regulatory oversight, the U.S. Food and Drug Administration (FDA) has proposed a rule targeted towards laboratory developed tests (LDTs), a move that could transform the landscape of medical testing.
For years, there has been a significant amount of discussion within the FDA regarding LDTs, and these discussions, coupled with failed congressional efforts, have ensued the need for broader oversight. Now, the FDA aims to implement a rule that would necessitate LDTs to comply with regulations for in vitro diagnostic devices (IVDs), according to a recent development cited by legal firm
Paul Hastings LLP.
LDTs, traditionally under the purview of the Centers for Medicare and Medicaid Services, have provided researchers and clinicians with a powerful tool used for various medical conditions and are constructed in a single laboratory. The proposed FDA rule could, for the first time, allow the regulatory agency to directly oversee LDTs and scrutinize them similarly to other IVDs, potentially facing new compliance requirements.
This new initiative signals the FDA’s intention to expand its regulatory authority in the healthcare arena, a change that could have major implications for laboratories, diagnostics companies, hospitals, and the broader healthcare industry. It is paramount that stakeholders in these sectors stay up to speed with these potential changes and understand the implications for their operations.
The proposed rule is still under consideration and the date for any possible implementation is yet to be determined. A broader analysis of the topic is available
here.